目的:研究CD4+ T细胞的抗肿瘤能力。方法:利用1例滤泡B淋巴细胞淋巴瘤患者的外周血淋巴细胞,将缺乏人类白细胞抗原Ⅰ(HLA-Ⅰ)的恶性CH1细胞株作为惟一的刺激源,以梯度稀释法,得到3种自体的、细胞毒性的、具有肿瘤杀伤特异性的CD4+ T细胞克隆。结果:3种T细胞克隆可以杀伤来自于新鲜恶性B细胞的自体HLA-Ⅰ分子缺乏的淋巴瘤细胞株,但却对EB病毒(EBV)阳性的正常B细胞或K562细胞无杀伤溶解作用。3种肿瘤特异杀伤的CD4+ T细胞均为TCR Vβ17-Dβ1-Jβ1.2,并具有同样的CDR3。结论:研究表明,CD4+ T细胞克隆能够被扩增,其能够特异性地杀伤从自体淋巴瘤细胞衍生的细胞株。通过产生CD4+ T细胞来杀伤肿瘤细胞及其相应的过继转移,特别是在肿瘤逃避CD8+T细胞介导的免疫杀伤作用时,CD4+ T细胞能起到替代作用。 Objective: To study the anti-tumor ability of CD4 + T cells. METHODS: Peripheral blood lymphocytes from a patient with follicular lymphoblastic lymphoma were used as the only stimulus. Using gradient dilution method, three kinds of autologous , Cytotoxic, tumor-specific CD4 + T cell clone. Results: Three kinds of T cell clones could kill lymphoma cell lines lacking autologous HLA-Ⅰ molecules derived from fresh malignant B cells, but had no killing effect on Epstein-Barr virus (EBV) -positive normal B cells or K562 cells. The three tumor-specific CD4 + T cells were both TCR Vβ17-Dβ1-Jβ1.2 and had the same CDR3. CONCLUSIONS: Studies have shown that CD4 + T cell clones can be expanded to specifically kill cell lines derived from autologous lymphoma cells. CD4 + T cells can kill tumor cells and their corresponding adoptive transfer by producing CD4 + T cells, especially when the tumor escapes CD8 + T cell-mediated immune killing.